论文部分内容阅读
目的:探讨西妥昔单抗与放化疗联合治疗方案对进展期鼻咽癌患者预后的影响。方法:收集2009年5月—2011年2月间诊治的进展期鼻咽癌患者64例,根据治疗方案将其分为观察组(n=36)和对照组(n=28),观察组患者给予西妥昔单抗与放化疗联合治疗方案治疗,对照组患者给予单纯放化疗治疗,分析两组患者的近期疗效、不良反应及3年内生存情况。结果:观察组患者治疗的总有效率66.67%高于对照组42.86%(P<0.05);两组患者不良反应发生情况经比较其差异无统计学意义(P>0.05);观察组患者3年内总生存率88.88%高于对照组67.86%(P<0.05)。结论:西妥昔单抗与放化疗联合治疗对进展期鼻咽癌患者的疗效较显著,未增加与放化疗相关的不良反应,安全性良好,有利于延长患者生存期。
Objective: To investigate the effects of cetuximab plus radiotherapy and chemotherapy on the prognosis of advanced nasopharyngeal carcinoma patients. Methods: Totally 64 advanced nasopharyngeal carcinoma patients were diagnosed and treated between May 2009 and February 2011. The patients were divided into observation group (n = 36) and control group (n = 28) Cetuximab and radiotherapy and chemotherapy combined treatment regimen, the control group of patients given radiotherapy and chemotherapy alone, the two groups of patients with short-term efficacy, adverse reactions and survival within 3 years. Results: The total effective rate of observation group was 66.67% higher than that of control group (42.86%) (P <0.05). There was no significant difference in adverse reactions between two groups (P> 0.05) The overall survival rate was 88.88% higher than the control group 67.86% (P <0.05). Conclusion: The combination therapy of cetuximab and radiotherapy and chemotherapy is more effective in patients with advanced nasopharyngeal carcinoma. It does not increase the adverse reactions associated with radiotherapy and chemotherapy, and has good safety and is beneficial to prolong the survival of patients.